Amorfix Life Sciences Ltd. announced that it will collaborate with QPS Holdings, LLC to further develop and validate its proprietary Alzheimer's disease diagnostic EP-AD assay. The companies will work together to obtain and analyze cerebral spinal fluid (CSF) samples from a variety of Alzheimer's disease patients in various stages of disease. Amorfix and QPS will perform the studies necessary to validate and ultimately commercialize the EP-AD assay for use as both a biomarker to facilitate clinical development of new treatments for AD, and an FDA-approved early-stage diagnostic test for AD.

To promote successful drug development within this challenging indication, QPS aims to explore new biomarkers that will facilitate early diagnosis and enable meaningful evaluation of drug efficacy for neurodegenerative disorders. Amorfix will also continue to provide the EP-AD assay for research use to pharmaceutical and biopharmaceutical companies on a fee for service basis.